



Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share

- » 2025 outlook confirmed
- » Board of Management and Supervisory Board actions ratified with large majority
- » Shareholders resolve dividend payment of EUR 0.90 per share

Grünwald, 26 June 2025 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today held its Annual General Meeting for financial year 2024. 14.6% of the share capital was in attendance at the Annual General Meeting, which was held in person. The majority of shareholders voted in line with the management's proposals under every agenda item.

The Annual General Meeting ratified the actions of all members of the Board of Management and of the Supervisory Board for financial year 2024 with a(n) 99.2% and 89.4% majority of votes cast, respectively. The Annual General Meeting acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.

Grant Thornton AG Wirtschaftsprüfungsgesellschaft was re-elected as the auditor for the current financial year. RSM Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft was chosen as auditor for the sustainability reporting. This is subject to the Corporate Sustainability Reporting Directive (CSRD) being transposed into national law, which will trigger the obligation to have the sustainability reporting for financial year 2025 audited. The detailed results of the voting for each agenda item are available on the Company website <https://ir.dermapharm.de/en/investor-relations/annual-general-meeting/> in the "Voting results" section under "Annual General Meeting 2025".

In financial year 2024, Dermapharm once again held its own as a rapidly growing provider in the European healthcare market. The Group lifted its revenue and net profit, exceeded the EBITDA forecast and set key strategic priorities for the future. The Board of Management and Supervisory Board would like to thank all employees for their dedication and commitment, which was instrumental to the success of the business. Looking ahead to 2025, Dermapharm is determined to stick with its chosen course.

"2025 will be a year of operational development. Our focus is on profitable growth through strong brands, targeted innovation and sustainable value creation throughout the supply chain. In the 'Branded pharmaceuticals' segment in particular, we expect further potential on the back of portfolio expansion and new momentum in the market. At the same time, we are driving forward our efforts to reorganise Arkopharma and realign our parallel import business with a clear strategy. This not only creates a foundation for long-term stability and business success, but positions us as a reliable partner for sustainable healthcare in Europe," explained Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.

Based on the course of business to date in 2025, the Board of Management confirmed the guidance for 2025 and expects consolidated revenue of EUR 1,160–1,200 million. Adjusted EBITDA is expected to grow to between EUR 322 million and EUR 332 million.



Company profile

Dermapharm – Pharmaceutical Excellence "Made in Europe"

Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Germany, the rest of Europe and the United States.

In the "Branded pharmaceuticals" segment, Dermapharm has more than 1,300 marketing authorisations with roughly 400 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company's integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.

Dermapharm bundles herbal pharmaceuticals, food supplements, cosmetics, medical devices, herbal extracts and medicinal cannabis in its "Other healthcare products" segment. In this segment, Dermapharm can tap the expertise of Arkopharma, the market leader for herbal food supplements in France, and the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm also operates the "Parallel import business" segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceutical wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently the sixth largest parallel importer in Germany.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233
E-mail: ir@dermapharm.com